This week at 'The Global Summit’, world leaders gathered to pledge support for @gavi, the Vaccine Alliance. Learn about GSK’s commitments, including our partnership that’s led to Bharat Biotech halving the price of the world's first malaria vaccine for children in endemic.

#News for #investors and #media: Bharat Biotech and GSK announce partnership impact and ambition ahead of Gavi, the Vaccine Alliance’s ‘Global Summit: Health & Prosperity through Immunisation.’ Learn more:

#News for #investors and #media: We're pleased to share the EMA has accepted for review the use of one of our investigational assets to treat cholestatic pruritus in patients with primary biliary cholangitis (PBC). Learn more here

#News for #investors and #media: Japan’s Ministry of Health, Labour and Welfare has accepted a regulatory application to expand the population indication for one of our vaccines. Access our website here

At GSK, we empower our team with data tech, including AI, to enhance skills and integrate innovation into every aspect of our work. Our focus on the complete patient journey ensures that we use technology to develop and deliver medicines and vaccines more efficiently than ever

Thanks for having us #LondonTechWeek! We’ve had a blast connecting with the tech community here in London and beyond. Find out more: #LTW25

#News for #investors and #media: Today we have announced that the European Medicines Agency (EMA) have accepted a regulatory submission to expand the population for one of our vaccines. Access our website here:

#News for #investors and #media: GSK out-licenses to Bharat Biotech for further vaccine development in diarrhoeal disease. Learn more:

We are at #EHA2025 in Milan presenting our research in challenging blood cancers, such as multiple myeloma and myelofibrosis. 🔗 Hear from people impacted by blood cancer and find out what scientists are doing to improve patient care:

At #LondonTechWeek, we captured some quick takes from our leaders on the buzzing show floor. These leaders share how tech is transforming our work today, and what excites them when they look ahead. To kick things off, our Chief Digital & Technology Officer, Shobie Ramakrishnan,

Scientists at GSK are using digital biological twins and organoids – miniature living replicas of tumours grown in a lab – to create personalised solutions for patients with cancer: #LTW25.

Using the power of technology, we're revolutionising the development and delivery of medicines and vaccines to make a real difference to people's health on a global scale. Through cutting-edge data tech and platform technologies, we delve deeper into patient care, human biology,

Heading to #LondonTechWeek? Join our leaders discussing everything from driving growth and transforming the future of healthcare, to exploring the impact of generative AI on drug discovery and the world of digital twins in drug development. 🔗 Can't make it? Learn how we are.

#ASCO25 may be over for another year but our drive to push the boundaries of innovation by combining science, technology and partnership to get head of cancer never stops. Hear from our oncology leaders as they reflect on this year’s conference. 🔗

At this year’s @ERAkidney congress, we’re focused on preventative measures in managing lupus nephritis to preserve kidney function. Early conversations between patients and doctors can facilitate a treatment plan to help reduce the risks of irreversible organ damage.

We're at #ASCO25, where we caught up with our oncology leaders Hesham and Nina. Curious to know what sets GSK Oncology apart? Let's hear what they had to say 👇. 🔗

Cancer is unrelenting, but so are we. We believe that getting ahead of disease is the best investment – for patients, communities, health systems, and economies. Learn more:

News for #investors and #media:. Today, we announced that the FDA has accepted a new drug application for a medicine to treat cholestatic pruritus in patients with primary biliary cholangitis (PBC). Learn more here:

We’re at #ASCO25 - showcasing groundbreaking cancer research at the world's largest oncology gathering. Hear from our CEO Emma Walmsley & SVP, Global Head Oncology R&D, Hesham Abdullah, as they share how we're tackling complex oncology challenges for patients. 🔗

Many blood cancer patients face lifelong treatment challenges, but thankfully scientists are working hard to give them the quality of life they deserve. We're sharing our progress in reshaping the landscape of cancer care at #ASCO25 .🔗